About Vidara Therapeutics
Vidara Therapeutics is a Healthcare company based in Alpharetta (United States) founded in 2011, and was acquired by Horizon Therapeutics in March 2014. Developer of protein based therapeutics for the treatment of chronic granulomatous disease and malignant osteopetrosis. Its chief executive, as recorded, is Tim Walbert. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its legal entity is Vidara Therapeutics Inc. Its competitors include Ultragenyx, Alnylam and Gemini Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Vidara Therapeutics was established in 2011 in Alpharetta, United States, within the biotechnology sector. Focus is placed on developing protein-based therapeutics to address chronic granulomatous disease and severe malignant osteopetrosis. Operations center on the lead candidate, Actimmune, a bioengineered interferon gamma-1b formulation designed to activate the immune system for disease management. Activities are conducted primarily in the United States, targeting rare immunological and bone disorders.
- Headquarters Alpharetta, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website vidararx.com
- Acquired by Horizon Therapeutics (Mar 2014)
- Legal Name Vidara Therapeutics Inc
- Investors
- Acquired byHorizon Therapeutics
(Mar 2014)
Investors in Vidara Therapeutics
Vidara Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Horizon Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of drugs for treating rare and autoimmune diseases | 2008 | horizontherapeutics.com | Dublin, Ireland |
Investor details for Vidara Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vidara Therapeutics
1 people are tracked at Vidara Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Tim Walbert | CEO | Leadership |
Complete people profiles for Vidara Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vidara Therapeutics
2 dated milestones of Vidara Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Vidara Therapeutics is founded.
- Exit Acquired by Horizon Therapeutics.
Competitors of Vidara Therapeutics
Vidara Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Ultragenyx, Alnylam and Gemini Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| geminitherapeutics.com | 2015 | Cambridge, United States | $44.5M | 45 | Developer of precision therapeutics for dry AMD and rare genetic diseases |
Detailed competitors of Vidara Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Vidara Therapeutics (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Vidara Therapeutics
Vidara Therapeutics was founded in 2011.
Vidara Therapeutics is headquartered in Alpharetta, United States. It is registered at Alpharetta, Georgia, United States.
Tim Walbert is the CEO of Vidara Therapeutics, as recorded in our data.
Vidara Therapeutics was established in 2011 in Alpharetta, United States, within the biotechnology sector. Focus is placed on developing protein-based therapeutics to address chronic granulomatous disease and severe malignant osteopetrosis. Operations center on the lead candidate, Actimmune, a bioengineered interferon gamma-1b formulation designed to activate the immune system for disease management. Activities are conducted primarily in the United States, targeting rare immunological and bone disorders.
Vidara Therapeutics's top competitors include Alnylam, Ultragenyx and Gemini Therapeutics.
Vidara Therapeutics has 1 investor. Key investors include Horizon Therapeutics.
Vidara Therapeutics operates through Vidara Therapeutics Inc.
Yes. Vidara Therapeutics was acquired by Horizon Therapeutics in March 2014.